Skip to content

D&A at other companies

ResMed logo
ResMedRMD
$58.98M+35.0%
LivaNova logo
LivaNovaLIVN
$8.3M+29.3%
Globus Medical logo
Globus MedicalGMED
$69.86M+6.4%
ITG
Integer HoldingsITGR
$35.01M+17.4%
Medtronic logo
MedtronicMDT
$716M-14.8%

Other financials

Income statement

See full
Revenue$204.6M+1.6%
Gross profit$176.9M+3.7%
Operating income-$1.1M+24.7%
Net income-$11.3M-477%
EPS (diluted)-$0.39-490%

Balance sheet

See full
Cash & equivalents$98.9M+83.6%
Total debt$29.6M-11.8%
Total equity$792.3M+24.6%
Total assets$911.4M+24.7%

Cash flow

See full
Operating cash flow$12.8M+292%
CapEx$9.7M+15.7%
Free cash flow$3.1M+121%

Valuation

See full
Market cap$1.24B-67.8%
Enterprise value$1.18B-69.4%
P/E9.5×-48.6×
P/S1.4×-3.2×

Profitability

See full
Gross margin85.8%+1.1pp
Operating margin5.6%-0.3pp
Net margin14.3%+6.4pp
FCF margin10.6%+1.2pp

Returns & leverage

See full
Return on equity18.4%+7.5pp
Debt / equity0.0×
Current ratio6.3×-2.7×

Where this comes from

Reported directly by Inspire Medical Systems in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Inspire Medical Systems’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inspire Medical Systems's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inspire Medical Systems's D&A?
Inspire Medical Systems (INSP) reported D&A of $5.11M in Q1 2026.
How has Inspire Medical Systems's D&A changed year-over-year?
Inspire Medical Systems's D&A increased by 67.9% year-over-year, from $3.04M to $5.11M.
What is the long-term trend for Inspire Medical Systems's D&A?
Over 4 years (2021 to 2025), Inspire Medical Systems's D&A has grown at a 84.0% compound annual growth rate (CAGR), from $1.22M to $13.96M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.